Spectral karyotyping (SKY) by Belloni, E et al.
Spectral karyotyping (SKY)
E Belloni , E Bonnomi , I Lahortiga , MD Odero , PP Di Fiore  and PG Pelicci
1,2 1,2 3 3 1,2,4 1,2,4
1Istituto Europeo di Oncologia, Milan, Italy 
2Campus IFOM-IEO, Milan, Italy 
3Department of Genetics, University of Navarra, Pamplona, Spain 
4Universita' degli Studi di Milano, Milan, Italy 
 
Published:  13/10/2010               Received: 02/02/2010 
 
ecancer 2010, 4:181 DOI: 10.3332/ecancer.2010.181 
 
Copyright:  © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
Competing Interests: The authors have declared that no competing interests exist. 
 
ecancermedicalscience 
 
1 
I
m
a
g
e
 
R
e
p
o
r
t
Correspondence to E Belloni. Email: elena.belloni@ifom-ieo-campus.itecancer 2010, 4:181 
 
 
 
Spectral karyotyping (SKY) enables the visualization of all 24 
human chromosomes assigned in different colours in a single 
metaphase, by using a combination of probe labelling, 
fluorescence microscopy, spectroscopy, CCD-imaging and 
spectral image analysis. The benefits of such an approach 
include the accurate analysis of abnormal karyotypes, 
unresolved by conventional cytogenetics and the ability to 
identify cryptic translocations in apparently 'normal' karyotypes. 
The labelling procedure is based on the utilization of five 
fluorochromes, differently combined for each specific 
chromosome. The SKY system (microscope and acquisition 
software) receives and processes the emitted signals, assigning 
a specific colour to a specific chromosome. In this image, the 
karyotype of a male affected by acute myeloid leukaemia is 
represented, showing the presence of the following 
rearrangements: del1q, balanced t(4;11) and balanced t(5;9). 
[Realized with the collaboration of Dr Idoya Lahortiga, visiting 
our institute in 2001.] 
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